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stricter HEC deﬁnition of thrust, and (2) restricting analyses to persons
with deﬁnite knee OA yielded similar results.
OR adjusted for all other factors in table
For VARUS thrust
(95%CI)
For VALGUS thrust
(95%CI)
African-American 0.74 (0.55, 0.98) 2.34 (1.56, 3.51)
Age (OR per 1 year) 1.03 (1.02, 1.04) 1.01 (0.99, 1.03)
Female 0.70 (0.57, 0.86) 0.77 (0.52, 1.14)
BMI (OR per 1 unit) 1.03 (1.01, 1.05) 0.98 (0.95, 1.02)
Knee injury 1.07 (0.89, 1.27) 0.82 (0.57, 1.18)
Knee surgery 1.03 (0.82, 1.31) 1.27 (0.82, 1.96)
K/L grade 1 1.25 (0.99, 1.57) 0.94 (0.60, 1.47)
K/L grade 2 0.89 (0.68, 1.18) 1.15 (0.71, 1.87)
K/L grade 3 1.59 (1.23, 2.05) 1.28 (0.79, 2.08)
K/L grade 4 2.17 (1.56, 3.03) 2.48 (1.44, 4.29)
Varus malalignment (OR per 1 degree) 1.05 (1.03, 1.07) −-
Valgus malalignment (OR per 1 degree) −- 1.10 (1.05, 1.16)
Knee extensor strength (OR per 20 units) 0.98 (0.98, 0.99) 1.00 (0.98, 1.01)
Conclusions: In sum, risk factors for prevalent varus thrust included C
race, male gender, and greater age, BMI, disease severity, and varus
malalignment. Risk factors for prevalent valgus thrust included AA race,
disease severity, and greater valgus malalignment. Varus thrust was
more common than valgus thrust. AA were at greater risk for hav-
ing a valgus thrust, in keeping with prior ﬁndings suggesting lateral
tibiofemoral OA may be more common in AA (Jordan et al, Arthritis
Rheum 2006;54:S307).
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FUNDED HEALTH CARE SYSTEM: IMPLICATIONS FOR
CARE DELIVERY
E.M. Badley1, M. Canizares2, C. MacKay2, A.M. Davis1. 1Arthritis
Community Research & Evaluation Unit; Toronto Western Research
Institute; University of Toronto, Toronto, ON, CANADA, 2Arthritis
Community Research & Evaluation Unit; Toronto Western Research
Institute, Toronto, ON, CANADA.
Purpose: Osteoarthritis (OA) is the most frequent type of arthritis, and
yet the requirements for patients with OA are rarely considered from a
health care system perspective. As part of the development of models to
care for OA, the purpose of this study is to document the amount and
type of care delivered for OA, including use of surgery.
Methods: The setting was a jurisdiction (population approx 12 million).
Analysis of all physician billings from health service administrative data
bases for all settings (primary care, emergency room, day surgery and
inpatient) by diagnostic code, physician type, and geographic area, for
years 2006−07. In addition all patients with OA seeing an orthopedic
surgeon in 2005, and who had not already had surgery in the previous
6 months, were followed for 18 months to monitor surgical events.
Results: 4.3% (approx 0.5 million people) of the population had a least 1
ambulatory visit with a diagnostic code of OA (1.1% for age 15−44; 6.8%
for age 45−64; 15.6% for age 65+). The mean number of visits was 1.9,
and the female:male ratio was 1.6:1. Ambulatory visits for OA represented
21% of all physician visits for musculoskeletal disorders and 5% of visits
to all physicians for all conditions. OA accounted for 38% of inpatient
hospitalizations and 8.6% of day surgeries, but <1% of emergency room
visits.
79% of ambulatory visits were to primary care physicians, and 30% to
specialists (10% saw both). Of specialist visits, 16% were to medical
specialists (5% to rheumatologists and 4% to general internists) and
21% to surgical specialists (almost all to orthopedics). Of those seeing a
surgeon (and with no surgery in previous 6 months) only 29% got surgery
within 18 months of the index visit: i.e. only an estimated 6% of people
with OA ambulatory visits to physicians received a surgical intervention.
Analysis by geographic area for those seeing specialists showed a trade
off between seeing medical and surgical specialists: in areas where a
higher proportion saw medical specialists there was a lesser proportion
who saw surgical specialists. This is likely inﬂuenced by availability of the
different types of practitioners.
Conclusions: Assuming an estimated prevalence of OA of >10%, less
than half have a physician visit each year, mostly to primary care, and a
very small minority have surgery. In view of the documented deﬁciencies
in the primary care management of arthritis, models of care for OA are
needed to ensure timely referral for the minority potentially needing joint
replacement or pain management, and to provide ongoing conservative
management including appropriate use of exercise and self management
for the majority.
351 ESTIMATING PREVALENCE OF PHYSICIAN-DIAGNOSED
OSTEOARTHRITIS IN CANADA USING MICROSIMULATION
W.M. Flanagan1, J.A. Kopec2, P. Fine`s1, M. Rahman2, E.C. Sayre2,
J. Cibere3, A.H. Anis3, E.M. Badley4. 1Statistics Canada, Ottawa,
ON, CANADA, 2Arthritis Research Centre of Canada, Vancouver, BC,
CANADA, 3University of British Columbia, Vancouver, BC, CANADA,
4University of Toronto, Toronto, ON, CANADA
Purpose: Our objective was to estimate the prevalence of physician-
diagnosed osteoarthritis (OA) in Canada. Reliable estimates of OA
prevalence in the general population are needed for surveillance and
assessment of resource utilization.
Methods: We used the Population Health Model (POHEM), a microsim-
ulation model of health, disease and mortality developed by Statistics
Canada, to generate prevalence of OA consistent with OA incidence data.
OA incidence was projected sufﬁciently far into the future to obtain stable
estimates of age-standardized prevalence rates in the general population.
The incidence rates used were estimated from administrative data on all
visits to health professionals and hospital admissions covered by the Med-
ical Services Plan (MSP) of British Columbia, Canada (BC) for the ﬁscal
years 1991/2 through 2000/1. They were estimated by age and sex for a
one-year period between April 1, 2000 and March 31, 2001 and excluded
prevalent cases from the previous 9 years.OA diagnosis was deﬁned as
either 2 visits to a health professional or the ﬁrst hospital separation with
a 3-digit ICD-9 code 715. We assumed the age-sex-speciﬁc rates would
be representative at the national level. Point prevalence rates by age
and sex were also estimated directly from administrative data from all
OA cases over the 10 year period still alive as of March 31, 2001. We
used the cross-sectional Canadian Community Health Survey (2000−01),
representing the household population, to estimate physician-diagnosed
OA from self-reported data.
Results: The overall prevalence rates of OA generated from the simula-
tion for the 2001 population aged 20 and older were 10.5% and 17.3% in
males and females, respectively. The overall prevalence rates directly
estimated from administrative data were 4.8% in males and 6.9% in
females. Self-reported prevalence of OA from survey data for persons
aged 20 and older was 5.8% in males and 12.3% in females for all age
groups combined. The rates were higher for females than males in all
age groups, except under age 45 in administrative data. After age 50,
rates increased approximately linearly with age, except in the survey data
where rates leveled off at age 75. By age 70−74, about one-third of men
and half of women had OA in the POHEM generated data. This was
considerably lower in administrative data (about 20% of men and 25%
of women had been diagnosed with OA) and self-reported survey data
(16% of men and one-third of women reported OA).
Conclusions: The POHEM microsimulation yielded estimates for preva-
lence of OA which were higher than those from physician visit adminis-
trative and self report data, and point to the large impact of this disease
in the population. This method has the advantage of overcoming some of
the limitations of relying solely on administrative data (insufﬁcient years
of data) or on self-report (such as recall bias, lack of saliency, and
ﬂuctuating disease symptoms). This method also offers the possibility
to study the impact of factors affecting incidence (e.g. increasing obesity)
for population surveillance and assessment of potential future resource
utilization.
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Purpose: To construct and describe energy expenditure and hip/knee
joint force measures, and the ratio between them, in different strata of
the population.
Methods: Design: Retrospective cohort. Setting: Canada-wide popula-
tion study.
Participants and Data Collection: Data source: baseline data from the
Physical Activity and Joint Health cohort, a population 3-cycle Internet
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study. Source population: Canadian Association of Retired Persons. Life-
time Physical Activity Questionnaire: Lifetime activity in three domains –
sport, occupation and domestic – was self-reported retrospectively via
a validated online computer-adaptive survey. For each speciﬁc activity
type (e.g., each individual sport, each occupation held) detailed questions
were asked regarding frequency, duration and intensity. Activities were
further deconstructed by time spent in major body movement type (e.g.,
walk, run, squat).
Exposures: Energy Expenditure: estimated by multiplying number of
hours spent in an activity by the average intensity of that activity, as-
signed using standardized metabolic equivalents and reported in MET-
hours/week.
Hip and knee (tibio-femoral) joint force was estimated as the product of
lifetime bodyweight, typical hip and knee force for speciﬁc activities and
time spent in speciﬁc activities, and reported in kg-hours/week. A lifetime
bodyweight trajectory was derived using current weight, weight at age
20, maximum weight, and interpolated using a lowess (non parametric
smooth) curve. The typical hip and knee joint force assigned to each
of the body movements was based on a comprehensive review of the
biomechanical literature and a survey of expert opinion.
Relative Joint Loading Index: the ratio of cumulative joint force to total
metabolic equivalent (done separately for hip and knee).
For each physical activity exposure, mean values for 5-year intervals over
a person’s lifetime, averaged over all subjects, were calculated.
Results: Complete baseline data was collected on 4,269 subjects. The
sample was 63% female with a mean age of 61.5 years and BMI of 27.5.
Overall, women had higher lifetime energy expenditure than men (126 vs
107 MET-hours/wk), and slightly higher hip (47.9 vs 43.3 kg-hrs/wk, ×100)
and knee force (54.2 vs 44.1 kg-hrs/wk, ×100). On balance of the activity
across domains, mean energy and joint force for ‘female household’
and ‘male occupation’ were similar. The higher overall scores among
women were attributable to signiﬁcantly higher energy expenditure and
joint forces from occupational activities compared to household activities
among men. Males expended approximately 2 times the mean energy
and 3 times the mean hip and knee force in sport as women; however
for both genders, sport had a much smaller contribution to joint force and
energy expenditure than the occupation and domestic domains. For both
hip and knee forces, the highest joint loading index score (most joint force
relative to energy expenditure) was for the male sport, while the lowest
score was for female occupation.
Conclusions: Joint force trajectories for the hip and knee were con-
structed from survey data, and followed expected trends by gender and
physical activity domain. These measures may help provide information
on the tolerance of the hip and knee joint to long term load. Comparing
energy expenditure trajectories to joint force trajectories revealed variation
in different population strata, indicating these measures may be useful for
separately analyzing the effects of energy expenditure and joint load on
health outcomes.
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Purpose: EULAR recommendations for the management of knee OA
(KOA) have been published in 2000, then 2003 and widely disseminated
in France. However, no study focused on the level of adhesion of rheuma-
tologists (RH) to these recommendations and their application in daily
clinical practice.
Objective: To compare self-declared level of adhesion of French rheuma-
tologists to the EULAR recommendations for the management of KOA
and the way they effectively manage patients in 2007.
Methods: This was a prospective observational cross-sectional study of
professional practice. RH randomly selected within a representative panel
of French RH were asked to answer a questionnaire assessing their level
of knowledge of the EULAR recommendations for knee OA and to rate
their adhesion to each of the latter (using a 0–100mm VAS). They had
then to describe 2 successive patients visiting for symptomatic knee OA,
and the treatments they prescribed. Data collected: Demographics of
RH and patients, knee OA history and level of symptoms at visit, non
pharmacologic and pharmacologic treatments prescribed on day of visit.
Statistics: descriptive: mean, median, standard deviation (sd).
Results: 214 RH from all French areas answered: mean age 50, 69%
men, 56% private ofﬁce-based, 41% both hospital- and private ofﬁce-
based. Mean number of knee OA patients seen monthly was 42. 374 pa-
tients were included: mean age 69±10 years, 66% women, BMI 29±6,
97% painful at visit, mean pain level on a VAS = 49±22mm under
treatment (93% received a pharmacological treatment), mean level of
handicap on a VAS = 49±21mm, morning stiffness in 48% of patients,
night pain in 24%, presence of knee effusion in 125 patients (33%). 38%
were at a Kellgren-Lawrence (KL) radiological grade 2, 44% at a KL 3,
9% at a KL 4. Knee OA symptoms were present for 6±5 years. Thirteen
had already undergone a total joint replacement (3%). Adhesion rates to
EULAR recommendations and prescriptions made in the “real life” appear
in the table.
Table. Comparisons of adhesion rates to EULAR recommendations for knee OA and the level of
real prescriptions by rheumatologists to patients in daily practice
EULAR recommendation (by rank of citation in the
publication)
Adhesion VAS
mm: m (sd)
N (%) of patients
who are prescribed
each modality on
visit day
Treatment combines pharmaco- and non pharmacologic 78.9 (14.2) 296 (79%)
Treatment must be individualized 78.8 (14.4) 100%
Treatment associates education, exercises, aids and
weight loss
74.1 (18.9) 303 (81%)
Paracetamol, ﬁrst line analgesic 64.4 (24.3) 109 (26%)
Topics are effective 52.2 (25.0) 87 (23%)
NSAIDs if non response/intolerance to paracetamol 71.4 (19.5) 77 (18%)
Opioids are useful alternative 64.7 (20.7) 69 (16%)
Sy-SADOA are effective on symptoms (oral/intra-articular) 66.7 (19.3) 266 (71%)
[143 (38%) oral/
123 (33%) IA]
Intra-articular steroids in case of knee ﬂare 82.1 (14.7) 55 (14.7%)
Total knee replacement if failure of medical treatment 80.2 (12.8) 21 (6%)
Conclusions: In general, EULAR recommendations for knee OA seem to
be both agreed and followed by French RH. However, the percentage of
patients receiving paracetamol is low and the number of patients having
IA steroids under the number of patients presenting with knee effusion
and/or night pain. Pain level rated by these treated patients remains over
the “patient acceptable symptom state”.
This study has partly been supported by a grant from Genevrier Labora-
tories, Soﬁa Antipolis, France.
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Purpose: EULAR recommendations for the management of knee OA
have been published in 2000, then 2003 and widely disseminated in
France. However, no study focused on the way patients were treated
since this dissemination, nor on patient’s perception of their treatment
and on their level of satisfaction or expectations.
Objective: To evaluate the level of satisfaction and expectations of knee
OA patients treated by French rheumatologists (RH) in 2007.
Methods: This was a prospective observational cross-sectional study.
RH randomly selected within a representative panel of French RH were
asked to answer a questionnaire assessing their level of knowledge of
the EULAR recommendations for knee OA and to rate their adhesion
to each. They had then to describe 2 successive patients visiting for
symptomatic knee OA, and their treatments. Patients were given by
their RH a questionnaire they had to answer at home on their level of
satisfaction and expectations with respect to the management of their
knee OA. Data collected: Demographics, knee OA history and level of
symptoms, overall satisfaction level regarding the management of their
knee OA, speciﬁc levels with respect to attention paid to pain, dysfunc-
tion, information provided, advice for daily activities, physiotherapy and
exercise, pharmacologic therapy and monitoring of potential side effects
scored on a 0–100mm VAS (0=not satisﬁed at all; 100 = completely
satisﬁed). Statistics: descriptive: mean, median, standard deviation (sd).
Results: 346 patients out of 374 (92.5%) included by 214 RH returned
their answers: mean age 69.1±9.8 years, 67% women, BMI 28.5±5.7,
pain on VAS=49.2±22.2 under treatment, presence of knee effusion in
116 patients (34%); 38% at a Kellgren-Lawrence (KL) radiological grade
2, 43% at a KL 3, 9% at a KL 4. Knee OA symptoms were present for
6.2±6.2 years; patients were followed by a practitioner for 4.5±4.6 years
(mean number of GP visited 1.3, mean number of orthopaedic surgeons
visited 0.5, mean number of RH visited 1.2).
